🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing globally, with figures suggesting over 82 million new cases annually. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Medical experts are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the American regulatory agency in December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This milestone signifies a significant shift in the management of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

As per results detailed in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which uses an injection and a pill. The study enrolled over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians treating patients have expressed hope. The availability of a one-pill regimen of this kind is seen as a "revolutionary step" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for people and to prevent the spread of untreatable gonorrhoea around the world.